Omnicell, Inc. (OMCL) — SEC Filings
Omnicell, Inc. (OMCL) — 36 SEC filings. Latest: 8-K (Apr 28, 2026). Includes 23 8-K, 6 10-Q, 2 DEF 14A.
View Omnicell, Inc. on SEC EDGAR
Overview
Omnicell, Inc. (OMCL) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 8-K filed on Dec 8, 2025: Omnicell, Inc. filed an 8-K on December 8, 2025, to report a Regulation FD Disclosure and Financial Statements and Exhibits. The filing does not contain specific financial figures or material events beyond the standard reporting requirements.
Sentiment Summary
Across 36 filings, the sentiment breakdown is: 1 bearish, 34 neutral, 1 mixed. The dominant filing sentiment for Omnicell, Inc. is neutral.
Filing Type Overview
Omnicell, Inc. (OMCL) has filed 23 8-K, 6 10-Q, 2 DEF 14A, 2 10-K, 1 8-K/A, 2 SC 13G/A with the SEC between Jan 2024 to Apr 2026.
Filings by Year
Recent SEC Filings (36)
Risk Profile
Risk Assessment: Of OMCL's 33 recent filings, 1 were flagged as high-risk, 10 as medium-risk, and 22 as low-risk. The overall risk profile suggests relatively low risk with generally favorable filings.
Financial Highlights
| Metric | Value |
|---|---|
| Revenue | $310,631,000 |
| Net Income | $5,462,000 |
| EPS | $0.12 |
| Debt-to-Equity | 0.60 |
| Cash Position | $180,053,000 |
| Operating Margin | 14.5% |
| Total Assets | $1,948,597,000 |
| Total Debt | $334,592,000 |
Key Executives
- Chief Executive Officer
- Dr. Robert L. Johnson
- Dr. David L. Schlotterbeck
- Carol J. Burt
Industry Context
Omnicell operates in the healthcare technology sector, specifically focusing on medication management and adherence solutions for hospitals and pharmacies. The industry is characterized by increasing demand for efficiency, patient safety, and cost reduction in healthcare delivery. Key trends include the adoption of automation, data analytics for improved patient outcomes, and integration with broader health IT systems.
Top Tags
financial-reporting (8) · corporate-governance (7) · 8-k (6) · financials (5) · 10-Q (4) · executive-compensation (4) · Healthcare Technology (3) · 8-K (3) · governance (3) · amendment (3)
Key Numbers
| Metric | Value | Context |
|---|---|---|
| Total Revenues (Q3 2025) | $310.631M | Increased from $282.420M in Q3 2024 |
| Net Income (Q3 2025) | $5.462M | Decreased from $8.630M in Q3 2024 |
| Net Income (YTD Q3 2025) | $4.078M | Swung from a net loss of $3.311M in YTD Q3 2024 |
| Cash and Cash Equivalents (Sep 30, 2025) | $180.053M | Decreased from $369.201M at Dec 31, 2024 |
| Repayment of Convertible Senior Notes | $175.000M | Major cash outflow in financing activities |
| Common Stock Repurchases | $77.600M | Significant cash outflow in financing activities |
| Shares Outstanding (Oct 29, 2025) | 44,876,522 | Reflects share repurchases |
| Diluted EPS (Q3 2025) | $0.12 | Decreased from $0.19 in Q3 2024 |
| Diluted EPS (YTD Q3 2025) | $0.09 | Improved from $(0.07) in YTD Q3 2024 |
| Net Cash Provided by Operating Activities (YTD Q3 2025) | $96.946M | Decreased from $131.407M in YTD Q3 2024 |
| SEC File Number | 000-33043 | Identifies the company's filing history with the SEC. |
| IRS Employer Identification Number | 94-3166458 | Unique tax identification number for the company. |
| Q2 2025 Total Revenue | $245.2M | down 12.5% from Q2 2024's $280.1M |
| Q2 2025 Product Revenue | $135.2M | down 20.5% from Q2 2024's $170.1M |
| Q2 2025 Net Income | $10.3M | down 59% from Q2 2024's $25.1M |
Forward-Looking Statements
- {"claim":"Vanguard will maintain a significant, passive stake in Omnicell, reflecting its long-term investment strategy.","entity":"The Vanguard Group","targetDate":"December 29, 2024","confidence":"high"}
Related Companies
Frequently Asked Questions
What are the latest SEC filings for Omnicell, Inc. (OMCL)?
Omnicell, Inc. has 36 recent SEC filings from Jan 2024 to Apr 2026, including 23 8-K, 6 10-Q, 2 DEF 14A. Each filing includes an AI-generated plain-English summary.
What is the overall sentiment of OMCL filings?
Across 36 filings, the sentiment breakdown is: 1 bearish, 34 neutral, 1 mixed. The dominant sentiment is neutral.
Where can I find Omnicell, Inc. SEC filings explained simply?
ReadTheFiling provides AI-powered plain-English summaries of all Omnicell, Inc. (OMCL) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.
What are the key financial highlights for Omnicell, Inc.?
Key financial highlights from Omnicell, Inc.'s most recent 10-Q include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.
What is the investment thesis for OMCL?
The investment thesis for OMCL includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.
Who are the key executives at Omnicell, Inc.?
Key executives identified across Omnicell, Inc.'s filings include Chief Executive Officer, Dr. Robert L. Johnson, Dr. David L. Schlotterbeck, Carol J. Burt.
What are the main risk factors for Omnicell, Inc. stock?
Of OMCL's 33 assessed filings, 1 were flagged high-risk, 10 medium-risk, and 22 low-risk.
What are recent predictions and forward guidance from Omnicell, Inc.?
Recent forward-looking statements from Omnicell, Inc. include guidance on {"claim":"Vanguard will maintain a significant, passive stake in Omnicell, reflecting its long-term investment strategy..